vs
Apellis Pharmaceuticals, Inc.（APLS）与UNIVERSAL TECHNICAL INSTITUTE INC（UTI）财务数据对比。点击上方公司名可切换其他公司
UNIVERSAL TECHNICAL INSTITUTE INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.1倍（$220.8M vs $199.9M），UNIVERSAL TECHNICAL INSTITUTE INC净利率更高（5.8% vs -29.5%，领先35.3%），UNIVERSAL TECHNICAL INSTITUTE INC同比增速更快（9.6% vs -5.9%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-19.2M），过去两年UNIVERSAL TECHNICAL INSTITUTE INC的营收复合增速更高（9.5% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
环球技术学院（UTI）是美国的营利性私立技术院校集团，1965年由罗伯特·斯威特创立，专注于提供职业技术类教育课程，培养符合产业需求的技能型人才，在美职业教育领域拥有较长的运营历史与行业经验。
APLS vs UTI — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $220.8M |
| 净利润 | $-59.0M | $12.8M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 7.1% |
| 净利率 | -29.5% | 5.8% |
| 营收同比 | -5.9% | 9.6% |
| 净利润同比 | -62.2% | -42.1% |
| 每股收益（稀释后） | $-0.40 | $0.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $220.8M | ||
| Q3 25 | $458.6M | $222.4M | ||
| Q2 25 | $178.5M | $204.3M | ||
| Q1 25 | $166.8M | $207.4M | ||
| Q4 24 | $212.5M | $201.4M | ||
| Q3 24 | $196.8M | $196.4M | ||
| Q2 24 | $199.7M | $177.5M | ||
| Q1 24 | $172.3M | $184.2M |
| Q4 25 | $-59.0M | $12.8M | ||
| Q3 25 | $215.7M | $18.8M | ||
| Q2 25 | $-42.2M | $10.7M | ||
| Q1 25 | $-92.2M | $11.4M | ||
| Q4 24 | $-36.4M | $22.2M | ||
| Q3 24 | $-57.4M | $18.8M | ||
| Q2 24 | $-37.7M | $5.0M | ||
| Q1 24 | $-66.4M | $7.8M |
| Q4 25 | -25.6% | 7.1% | ||
| Q3 25 | 48.7% | 11.2% | ||
| Q2 25 | -18.6% | 6.9% | ||
| Q1 25 | -50.0% | 8.1% | ||
| Q4 24 | -12.3% | 13.6% | ||
| Q3 24 | -24.0% | 13.3% | ||
| Q2 24 | -14.7% | 4.2% | ||
| Q1 24 | -36.0% | 6.1% |
| Q4 25 | -29.5% | 5.8% | ||
| Q3 25 | 47.0% | 8.4% | ||
| Q2 25 | -23.6% | 5.2% | ||
| Q1 25 | -55.3% | 5.5% | ||
| Q4 24 | -17.1% | 11.0% | ||
| Q3 24 | -29.2% | 9.6% | ||
| Q2 24 | -18.9% | 2.8% | ||
| Q1 24 | -38.5% | 4.2% |
| Q4 25 | $-0.40 | $0.23 | ||
| Q3 25 | $1.67 | $0.33 | ||
| Q2 25 | $-0.33 | $0.19 | ||
| Q1 25 | $-0.74 | $0.21 | ||
| Q4 24 | $-0.30 | $0.40 | ||
| Q3 24 | $-0.46 | $0.35 | ||
| Q2 24 | $-0.30 | $0.09 | ||
| Q1 24 | $-0.54 | $0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $162.8M |
| 总债务越低越好 | — | $101.4M |
| 股东权益账面价值 | $370.1M | $335.9M |
| 总资产 | $1.1B | $834.0M |
| 负债/权益比越低杠杆越低 | — | 0.30× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $162.8M | ||
| Q3 25 | $479.2M | $169.1M | ||
| Q2 25 | $370.0M | $70.7M | ||
| Q1 25 | $358.4M | $96.0M | ||
| Q4 24 | $411.3M | $172.0M | ||
| Q3 24 | $396.9M | $161.9M | ||
| Q2 24 | $360.1M | $115.5M | ||
| Q1 24 | $325.9M | $116.1M |
| Q4 25 | — | $101.4M | ||
| Q3 25 | — | $87.1M | ||
| Q2 25 | — | $73.8M | ||
| Q1 25 | — | $94.4M | ||
| Q4 24 | — | $120.1M | ||
| Q3 24 | — | $125.7M | ||
| Q2 24 | — | $137.3M | ||
| Q1 24 | $93.1M | $141.9M |
| Q4 25 | $370.1M | $335.9M | ||
| Q3 25 | $401.2M | $328.1M | ||
| Q2 25 | $156.3M | $306.8M | ||
| Q1 25 | $164.2M | $293.9M | ||
| Q4 24 | $228.5M | $280.0M | ||
| Q3 24 | $237.1M | $260.2M | ||
| Q2 24 | $264.3M | $239.4M | ||
| Q1 24 | $266.7M | $232.6M |
| Q4 25 | $1.1B | $834.0M | ||
| Q3 25 | $1.1B | $826.1M | ||
| Q2 25 | $821.4M | $740.8M | ||
| Q1 25 | $807.3M | $720.4M | ||
| Q4 24 | $885.1M | $753.8M | ||
| Q3 24 | $901.9M | $744.6M | ||
| Q2 24 | $904.5M | $706.0M | ||
| Q1 24 | $831.9M | $702.1M |
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.32× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.48× | ||
| Q2 24 | — | 0.57× | ||
| Q1 24 | 0.35× | 0.61× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $3.1M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-19.2M |
| 自由现金流率自由现金流/营收 | -7.1% | -8.7% |
| 资本支出强度资本支出/营收 | 0.1% | 10.1% |
| 现金转化率经营现金流/净利润 | — | 0.24× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $16.6M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $3.1M | ||
| Q3 25 | $108.5M | $57.1M | ||
| Q2 25 | $4.4M | $18.1M | ||
| Q1 25 | $-53.4M | $-789.0K | ||
| Q4 24 | $19.4M | $23.0M | ||
| Q3 24 | $34.1M | $67.5M | ||
| Q2 24 | $-8.3M | $10.0M | ||
| Q1 24 | $-133.0M | $-2.5M |
| Q4 25 | $-14.3M | $-19.2M | ||
| Q3 25 | $108.3M | $40.6M | ||
| Q2 25 | $4.4M | $6.8M | ||
| Q1 25 | $-53.4M | $-11.7M | ||
| Q4 24 | $19.3M | $19.6M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | $-8.4M | $3.0M | ||
| Q1 24 | $-133.3M | $-8.4M |
| Q4 25 | -7.1% | -8.7% | ||
| Q3 25 | 23.6% | 18.3% | ||
| Q2 25 | 2.5% | 3.4% | ||
| Q1 25 | -32.0% | -5.7% | ||
| Q4 24 | 9.1% | 9.7% | ||
| Q3 24 | — | 30.6% | ||
| Q2 24 | -4.2% | 1.7% | ||
| Q1 24 | -77.3% | -4.6% |
| Q4 25 | 0.1% | 10.1% | ||
| Q3 25 | 0.0% | 7.4% | ||
| Q2 25 | 0.0% | 5.5% | ||
| Q1 25 | 0.0% | 5.3% | ||
| Q4 24 | 0.0% | 1.7% | ||
| Q3 24 | 0.0% | 3.8% | ||
| Q2 24 | 0.0% | 4.0% | ||
| Q1 24 | 0.2% | 3.2% |
| Q4 25 | — | 0.24× | ||
| Q3 25 | 0.50× | 3.04× | ||
| Q2 25 | — | 1.69× | ||
| Q1 25 | — | -0.07× | ||
| Q4 24 | — | 1.04× | ||
| Q3 24 | — | 3.58× | ||
| Q2 24 | — | 2.01× | ||
| Q1 24 | — | -0.32× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
UTI
| UTI | $142.8M | 65% |
| Concorde | $78.0M | 35% |
